Message from the Director of the Department
We are mainly in charge of the diagnosis and medical care of chest and respiratory diseases. Current medical strategies for respiratory diseases are now reaching a turning point.
Particularly in non-small cell lung cancer, precision medicine using genomic information from each patient has been developed. We try to improve the medical care for patients with respiratory diseases through clinical trials and translational research. We continue to strive to provide the best medical care for our patients.
Department of Allergy and
Respiratory MedicineKatsuyuki Kiura
Scope of Target Disease
We mainly diagnose and treat thoracic malignant neoplasms and respiratory and allergic diseases.
Among thoracic malignant neoplasms, we provide anti-cancer therapy for lung cancer, thymoma/thymic carcinoma, and malignant pleural mesothelioma. In collaboration with the center for clinical oncology, we provide chemotherapy for various advanced malignant tumor types, including breast cancer, ovarian cancer, germ cell tumor, osteosarcoma, soft tissue sarcoma, stomach cancer, colon cancer, head and neck cancer, thyroid cancer, and unknown primary cancer.
Among respiratory diseases, we provide medical care for bronchial asthma, eosinophilic pneumonia, hypersensitivity pneumonitis, chronic obstructive pulmonary disease (COPD), diffuse panbronchiolitis (DPB), idiopathic interstitial pneumonia (IIPs), collagen lung disease, sarcoidosis, drug-induced pneumonia, bacterial pneumonia, pulmonary mycobacterium infection, pulmonary mycosis infection, pleural disease, acute respiratory distress syndrome (ARDS), and sleep apnea syndrome.
Features and Description of Medical Care
We have reported good treatment outcomes in clinical trials that we have conducted. In patients with locally advanced lung cancer, we actively plan tri-modality combination therapy using cytotoxic chemotherapy, chest radiotherapy, and surgery.
Additionally, we use precision medicine methods, treatment with novel molecule-targeted drugs suitable for the tumor genomic information in each patient. Furthermore, we are involved in clinical trials for new immunotherapies, including immune checkpoint inhibitors.
In respiratory and allergic diseases, we investigate causes for various symptoms and formulate an appropriate treatment plan according to their etiology. For bronchial asthma, we aim to allow patients a life similar to that of healthy people by providing treatment with inhaled corticosteroids and bronchodilators. We also positively consider the introduction of antibody preparations such as anti-IgE antibody and anti-IL-5 antibody, to treat severe asthma. For interstitial lung diseases, we plan the diagnosis and optimal treatment by performing bronchoscopy based on CT images.